Related Experiment Video
Updated: Mar 24, 2026
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors
Michael J Allegrezza1, Melanie R Rutkowski1, Tom L Stephen1
1Tumor Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania.
Abstract:
Many signal transduction inhibitors are being developed for cancer therapy target pathways that are also important for the proper function of antitumor lymphocytes, possibly weakening their therapeutic effects. Here we show that most inhibitors targeting multiple signaling pathways have especially strong negative effects on T-cell activation at their active doses on cancer cells. In particular, we found that recently approved MEK inhibitors displayed potent suppressive effects on T cells in vitro However, these effects could be attenuated by certain cytokines that can be administered to cancer patients. Among them, clinically available IL15 superagonists, which can activate PI3K selectively in T lymphocytes, synergized with MEK inhibitors in vivo to elicit potent and durable antitumor responses, including by a vaccine-like effect that generated resistance to tumor rechallenge. Our work identifies a clinically actionable approach to overcome the T-cell-suppressive effects of MEK inhibitors and illustrates how to reconcile the deficiencies of signal transduction inhibitors, which impede desired immunologic effects in vivo Cancer Res; 76(9); 2561-72. ©2016 AACR.
Insights
Signal transduction inhibitors harm T-cell function in cancer therapy. Combining MEK inhibitors with IL15 superagonists enhances antitumor immunity and overcomes T-cell suppression.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Background:
- Signal transduction inhibitors are crucial cancer therapeutics.
- These inhibitors can impair antitumor lymphocyte function, potentially limiting efficacy.
- Understanding these interactions is vital for optimizing cancer treatment.
Purpose of the Study:
- To investigate the impact of signal transduction inhibitors on T-cell activation.
- To identify strategies for mitigating the immunosuppressive effects of these inhibitors.
- To explore combination therapies for enhanced antitumor responses.
Main Methods:
- Assessed the effects of MEK inhibitors on T-cell activation in vitro.
- Evaluated the potential of cytokines to attenuate inhibitor-induced T-cell suppression.
- Investigated the in vivo efficacy of combining MEK inhibitors with IL15 superagonists.
Main Results:
- Most multi-targeting signal transduction inhibitors negatively affected T-cell activation.
- MEK inhibitors showed potent suppressive effects on T cells in vitro.
- IL15 superagonists attenuated MEK inhibitor-induced T-cell suppression and synergized to produce durable antitumor responses.
Conclusions:
- Clinically available IL15 superagonists can overcome T-cell suppression by MEK inhibitors.
- Combination therapy with MEK inhibitors and IL15 superagonists elicits potent and durable antitumor immunity.
- This approach offers a strategy to reconcile signal transduction inhibitor deficiencies and enhance desired immunologic effects.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Related Concept Videos
01:27Tumor Immunotherapy
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents